Pedro Acuna Taboada
Hello everyone! Big news for $NVO (Novo-Nordisk A/S SPONS ADR) today. ๐—๐˜‚๐˜€๐˜ ๐—ฎ ๐—ณ๐—ฒ๐˜„ ๐—บ๐—ถ๐—ป๐˜‚๐˜๐—ฒ๐˜€ ๐—ฎ๐—ด๐—ผ ๐˜๐—ต๐—ฒ ๐—™๐——๐—” ๐—ฎ๐—ฝ๐—ฝ๐—ฟ๐—ผ๐˜ƒ๐—ฒ๐—ฑ ๐˜๐—ต๐—ฒ ๐—ผ๐—ฟ๐—ฎ๐—น ๐˜ƒ๐—ฒ๐—ฟ๐˜€๐—ถ๐—ผ๐—ป ๐—ผ๐—ณ ๐—ช๐—ฒ๐—ด๐—ผ๐˜ƒ๐˜†, providing a needle free alternative that significantly expands the addressable market for $NVO. This is the first step on my thesis on $NVO's recovery. So what I'm expecting for 2026: โ—พEarly January: Pill available in the US (confirmed). โ—พThroughout the year: Improving numbers and guidance. โ—พLate 2026: Approval in Europe. Now is time to wait and see how things develop. So far the stock is up ~ 9% in after hours market.
Not investment advice. The author may have financial interests in the mentioned instruments.
null
.